Latest Trends of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-i) for Heart Failure (HF) and Chronic Kidney Disease (CKD)

Author:

Bando Hiroshi1ORCID

Affiliation:

1. Medical Research/Tokushima University, Tokushima, Japan; Japan Low Carbohydrate Diet Promotion Association, Kyoto, Japan

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) have been effective for heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes (T2D). Among SGLT2-i, empagliflozin and dapagliflozin were compared for clinical effect, with empagliflozin showing a lower composite of all-cause mortality or hospitalization with a hazard ratio (HR) of 0.90. In the EMPA-ELDERLY clinical trial, empagliflozin demonstrated better HbA1c reduction and weight reduction without affecting muscle strength or mass in elderly patients with T2D. The American College of Physicians (ACP) published “Newer Pharmacologic Treatments in Adults with Type 2 Diabetes” in April 2024. The potential mechanisms for the anti-inflammatory effects of SGLT2-i will be clarified in the future.

Publisher

Asploro Open Access Publications

Reference12 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3